Jun 4, 2026 04:48PM
Jun 2, 2026 08:01AM
Jun 2, 2026 08:00AM
May 26, 2026 06:59AM
May 14, 2026 08:03AM
May 14, 2026 08:00AM
Apr 6, 2026 04:34PM Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Mar 18, 2026 08:00AM
Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM
Nov 18, 2025 04:27PM
Nov 13, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Oct 28, 2025 08:01AM
Oct 28, 2025 08:00AM
Oct 23, 2025 04:45PM
Oct 14, 2025 08:04AM
Oct 14, 2025 08:00AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Aug 21, 2025 04:35PM
Aug 19, 2025 08:45AM
Aug 15, 2025 09:02AM
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM Cingulate receives $4.3 million FDA fee waiver for ADHD drug application
Jul 29, 2025 08:00AM
Jul 9, 2025 08:03AM
Jul 9, 2025 08:00AM
Jun 18, 2025 08:00AM
May 20, 2025 08:03AM
May 20, 2025 08:00AM
May 14, 2025 08:04AM Cingulate Inc (CING): FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
May 14, 2025 08:00AM
May 8, 2025 04:30PM
Apr 29, 2025 08:00AM
Apr 3, 2025 08:06AM
Apr 3, 2025 08:00AM
Mar 26, 2025 05:00PM
Mar 4, 2025 09:02AM Cingulate Inc (CING) Reports Safety Results from Final Phase 3 Trials for CTx-1301
Mar 4, 2025 09:00AM
Jan 30, 2025 06:40AM
Jan 7, 2025 07:30AM
Dec 23, 2024 07:30AM
Nov 7, 2024 07:30AM
Sep 12, 2024 08:30AM
Aug 15, 2024 07:45AM Cingulate Inc (CING) Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
Aug 15, 2024 07:45AM

322,935 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All